Core Insights - Tempus AI is adopting a dual-engine model focusing on a rapidly growing Genomics franchise and a scaling data business supported by an expanding AI toolkit [1][2] - The company achieved non-GAAP profitability in Q3 2025, indicating operational momentum as revenue increases [1][8] - The revenue mix is primarily from North America, driven by oncology testing, hereditary screening, and a developing minimal residual disease (MRD) offering [1][2] Genomics and Data Services - Tempus AI aggregates multimodal clinical and lab data, commercializing it through Genomics and Data services, including an Insights platform [2] - The Genomics portfolio aids in therapy selection and disease monitoring through various DNA and RNA-based tests, while the Insights platform monetizes de-identified datasets and analytics for life sciences partners [2][9] - In 2024, Genomics accounted for approximately 65% of revenue, with Data and services contributing 35%, highlighting the growing significance of data licensing [9] Operating Performance - The company reached a key milestone of non-GAAP profitability in Q3, supported by disciplined MRD expansion and cost management [3][8] - EPS history and estimates show a trend towards reduced losses into 2026, reflecting operational leverage from scaling and improved revenue mix [3] Regulatory and Payment Factors - Tempus AI is working on Advanced Diagnostic Laboratory Test (ADLT) migrations, which could enhance pricing and reimbursement opportunities [4][8] - Current average reimbursement rates are below peers, and successful execution of ADLT transitions and payer coverage expansion is crucial for revenue quality and margin improvement [4][8] Growth Drivers - Growth is expected to be driven by increased MRD volumes as the adoption of the xM test expands and new use cases are identified [11] - Recent performance included a 31.3% EPS surprise and a 2.4% sales surprise, providing a positive context for upcoming financial results [11] Competitive Landscape - Illumina and Guardant Health are key competitors in the genomic tools and clinical applications space, providing insights into oncology testing demand and reimbursement pathways relevant to Tempus AI [12]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Core Viewpoint - Kamada Ltd. has decided to discontinue its Phase 3 InnovAATe trial for Inhaled AAT aimed at treating Alpha-1 Antitrypsin Deficiency (AATD) due to low likelihood of demonstrating a statistically significant benefit in lung function [1][3]. Company Updates - The discontinuation of the trial follows advice from an independent Data and Safety Monitoring Board (DSMB) based on a prespecified interim futility analysis [3]. - CEO Amir London expressed disappointment over the trial's outcome but emphasized the company's strong position for future growth prospects [4]. - Kamada reiterated its full-year 2025 revenue guidance of $178 million to $182 million, aligning closely with the consensus of $180.66 million, and provided adjusted EBITDA guidance of $40 million to $44 million [5]. Future Outlook - The company projects double-digit growth in revenues and profitability for 2026, supported by its commercial portfolio, which includes six FDA-approved specialty plasma-derived products marketed in over 30 countries [6]. - Kamada is also focusing on expanding its biosimilar portfolio in Israel and increasing plasma collection capacity, while pursuing new business development opportunities to ensure long-term growth [6]. Market Reaction - Following the announcement, Kamada's stock experienced a decline of 5.51%, trading at $6.69 [7].

The US Congress is poised to enact bipartisan legislation that would block some Chinese biotechnology companies from government-funded contracts https://t.co/fas76DrS6r ...

Economic Overview - The U.S. economy is experiencing persistent inflation and slowing job growth, increasing the likelihood of interest rate cuts by the Federal Reserve [1] - Tariffs, supply-chain issues, and inconsistent business investment are negatively impacting economic growth, making it challenging for retail investors to interpret market signals and achieve solid returns [1] Broker Recommendations - Following brokers' recommendations can simplify investment decisions, with stocks like Illumina, Inc. (ILMN), Commercial Metals Company (CMC), and Newmont Corporation (NEM) being highlighted as potential opportunities [2] - Brokers provide insights through direct engagement with company management, analysis of public disclosures, and participation in earnings calls, which helps evaluate a company's fundamentals in the broader economic context [3] Stock Upgrades - Broker upgrades are often based on new information, earnings surprises, improving industry conditions, margin expansion, balance-sheet improvements, or attractive valuations relative to growth [4] - While broker upgrades are valuable, they should not be the sole basis for investment decisions; long-term returns require consideration of multiple factors including fundamental strength and industry dynamics [5] Stock Screening Strategy - A screening strategy identifies stocks with broker rating upgrades of 1% or more over the past four weeks, priced above $5, and with an average 20-day trading volume greater than 100,000 [6] - Stocks with a Zacks Rank of 1 (Strong Buy) or 2 (Buy) have a proven track record, and those with a VGM Score of A or B combined with a Zacks Rank 1 or 2 show the best upside potential [7] Company Highlights - Illumina, based in San Diego, specializes in sequencing and array-based solutions for genetic analysis, with a projected earnings increase of 92.2% year-over-year in 2025 and a 5% broker rating upgrade in the last four weeks [8][9] - Commercial Metals, located in Irving, TX, focuses on manufacturing and recycling steel and metal products, expecting an 87.5% earnings surge in fiscal 2026 with an 8.3% broker rating upgrade [10][11] - Newmont, one of the largest gold producers globally, anticipates a 74.1% earnings increase in 2025, supported by a 4.8% broker rating upgrade in the past four weeks [10][12]

Core Viewpoint - Moderna (MRNA) is showing potential as a strong investment opportunity due to its recent technical indicators and positive earnings revisions [1][2][3] Technical Analysis - MRNA has recently reached a key support level and has surpassed the 200-day moving average, indicating a long-term bullish trend [1] - The 200-day simple moving average serves as a significant indicator for determining overall market trends [1] Performance Metrics - Over the past four weeks, MRNA has experienced a rally of 12.9% [2] - The company currently holds a Zacks Rank of 3 (Hold), suggesting it may be poised for further upward movement [2] Earnings Estimates - There have been 9 upward revisions in earnings estimates for the current fiscal year, with no downward revisions, indicating strong positive sentiment [2] - The consensus earnings estimate for MRNA has also increased, reinforcing the bullish outlook [2] Investment Consideration - Given the favorable technical indicators and positive earnings revisions, MRNA should be considered for inclusion on investors' watchlists [3]

Core Insights - The combination of ziftomenib with venetoclax and azacitidine shows promising clinical activity in treating acute myeloid leukemia (AML) with NPM1 mutations, achieving an 86% composite complete remission (CRc) rate in newly diagnosed patients and a 65% overall response rate (ORR) in relapsed/refractory cases [1][2][5] - Ziftomenib has a favorable safety profile, with low rates of myelosuppression and manageable side effects, supporting its potential integration into treatment regimens for AML [4][7][8] - Ongoing registrational trials for ziftomenib are expected to further establish its role in both front-line and relapsed/refractory settings for AML [2][8][13] Summary by Category Clinical Efficacy - In newly diagnosed NPM1-m AML, 86% of patients achieved CRc, with 68% of responders attaining molecular minimal residual disease (MRD) negativity [1][3] - In relapsed/refractory NPM1-m AML, the ORR was 65%, and in venetoclax-naïve patients, it increased to 83% [2][11] - For KMT2A-r AML, the ORR was 41%, with 70% in venetoclax-naïve patients [1][11] Safety Profile - The triplet combination of ziftomenib, venetoclax, and azacitidine was well tolerated, with low rates of ziftomenib-related myelosuppression [4][7] - Adverse events included one case of grade 2 differentiation syndrome and one case of grade 3 QTc prolongation, both managed without treatment discontinuation [4][7] Ongoing Development - Kura Oncology is conducting registrational trials for ziftomenib in both intensive chemotherapy-eligible and -ineligible patients [1][2] - The company is also activating sites for pivotal trials, indicating confidence in the drug's potential as a foundational treatment for AML [8][13]

Financial Status & Milestones - Theravance Biopharma had approximately $333 million in cash with no debt and expects to remain at similar levels in Q4 2025 [7] - The company anticipates $175 million in near-term milestones based on TRELEGY and YUPELRI sales [7] - Theravance Biopharma has a 35% U S profit share with Viatris for YUPELRI, with IP protection into 2039 [7] Ampreloxetine & CYPRESS Trial - Ampreloxetine targets approximately 40,000 underserved patients in the U S with symptomatic nOH due to MSA [7] - The Phase 3 CYPRESS trial completed enrollment in Q3 2025, with topline data expected in Q1 2026 [7] - In a REDWOOD pre-specified MSA subgroup analysis (n=40), the greatest difference was observed in the 6-item OHSA composite score [48, 51] - Approximately 70-80% of patients with MSA will develop nOH in their lifetime, and despite treatment with available pressor agents, 68% remain symptomatic [30] Commercial Opportunity - The U S market includes approximately 40,000 MSA patients with nOH [7, 83, 96] - Only approximately 34% of patients are currently treated, indicating a significant unmet need [84] - The average launch price for chronic neurology therapies is approximately $333,000 [111]

智通财经APP获悉，周一，Kymera Therapeutics(KYMR.US)开盘大涨超40%，创历史新高，现报95.66美 元。消息面上，KYMR公司旗下药物KT-621的扩大性1b期特应性皮炎试验结果显示，在100毫克与200 毫克剂量组中均实现了深度STAT6降解，皮肤与血液中的降解率中位数分别达到94%和98%，显示出从 健康志愿者到特应性皮炎(AD)患者的强大转化能力。KT-621在血液中与疾病相关的2型生物标志物方面 表现出显著降低，包括胸腺活化调节趋化因子(TARC)(基线水平与dupilumab AD研究相当的患者中位下 降74%)、Eotaxin-3、IL-31、IgE以及皮肤病变中核心2型炎症和相关基因集合。 KT-621针对中重度AD的BROADEN2 2b期试验正在进行中，预计2027年中期获得数据。针对中重度哮 喘患者的2b期BREADTH试验计划于2026年第一季度启动。 ...

Economic Performance - Guangzhou's GDP has reached 3.1 trillion yuan, with an economic increment of approximately 700 billion yuan over the past five years [1] - The city has maintained a "double trillion, double growth" trend in social retail sales and foreign trade, becoming the third city in China to achieve this [1] Industrial Transformation - Industrial investment surged by 66%, from 103 billion yuan in 2020 to 171 billion yuan in 2024 [2] - The "12218" modern industrial system aims to rejuvenate traditional industries and promote emerging sectors [2] Emerging Industries - Strategic emerging industries such as new displays, biomedicine, and autonomous driving are leading nationally [3] - The production capacity for new display panels is expected to grow from 30 million square meters to over 43 million square meters, a growth of over 40% [3] Innovation Ecosystem - Guangzhou has over 13,500 high-tech enterprises, with 24 unicorn companies, three times the number from 2020 [6] - The city has established technology transfer centers to facilitate the commercialization of research outcomes [7] Regional Integration - The Greater Bay Area has seen significant connectivity improvements, with six cross-river channels and a new intercity railway network [8] - The city has implemented 99 measures to align with Hong Kong and Macau regulations, enhancing cross-border cooperation [9] Economic Growth in Nansha - Nansha's GDP has surpassed 230 billion yuan, attracting over 3,500 Hong Kong and Macau enterprises [10]